Should Empagliflozin Be Continued?
Do not stop empagliflozin for this creatinine rise from 100 to 158 µmol/L (approximately 1.13 to 1.79 mg/dL). This represents an expected, reversible hemodynamic effect that is not an indication to discontinue therapy.
Understanding the Expected eGFR Dip
An initial decline in eGFR is a normal, expected response to SGLT2 inhibitor initiation and reflects beneficial hemodynamic changes (reduced intraglomerular pressure) rather than kidney injury 1, 2, 3.
The KDIGO 2022 guideline explicitly states: "A reversible decrease in the eGFR with commencement of SGLT2i treatment may occur and is generally not an indication to discontinue therapy" 2.
In clinical trials, empagliflozin caused an acute eGFR decline of approximately 3-5 mL/min/1.73 m² within the first 2-4 weeks, which then stabilized 4, 3.
This initial dip is followed by long-term kidney protection: after the acute phase, empagliflozin slows chronic eGFR decline from -2.75 to -1.37 mL/min/1.73 m² per year (50% reduction) 5, 3.
Upon drug discontinuation, eGFR returns toward baseline, confirming the hemodynamic (not structural) nature of the initial decline 6, 3, 7.
When to Continue Empagliflozin
Continue empagliflozin even with declining eGFR unless specific contraindications arise 1, 4, 2:
The 2025 ADA Standards recommend continuing SGLT2 inhibitors for cardiovascular and kidney benefit "until dialysis or transplantation," even when glucose-lowering efficacy diminishes below eGFR 45 mL/min/1.73 m² 8.
KDIGO 2022 explicitly states: "Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 20 ml/min per 1.73 m², unless it is not tolerated or kidney replacement therapy is initiated" 2.
The EMPA-KIDNEY trial demonstrated kidney protection benefits in patients with eGFR as low as 20 mL/min/1.73 m² 9, 10.
Monitoring Strategy
Reassess creatinine 2-4 weeks after the initial rise 2:
- If creatinine stabilizes or improves after the initial dip, continue empagliflozin.
- Monitor for signs of true acute kidney injury (AKI) rather than expected hemodynamic changes 11.
- Urine microscopy can help differentiate hemodynamic changes from true tubular injury if clinical concern exists 11.
When to Actually Stop Empagliflozin
Discontinue empagliflozin only in these specific situations 1, 2:
- Symptomatic hypotension unresponsive to volume management
- Uncontrolled hyperkalemia despite medical treatment
- Acute illness, surgery, or prolonged fasting (temporary withholding for ketoacidosis risk) 1, 2
- Initiation of kidney replacement therapy 2
- True AKI from another cause (sepsis, contrast nephropathy, etc.) 2
Volume Status Assessment
Before attributing creatinine rise to empagliflozin, evaluate for volume depletion 1, 2:
- Assess for symptoms of volume depletion (dizziness, orthostatic hypotension)
- Consider reducing concurrent diuretics if volume depletion is present 1, 2
- Correct any volume depletion and reassess kidney function 2
Key Pitfall to Avoid
The most common error is prematurely discontinuing empagliflozin due to the expected initial eGFR dip, thereby depriving patients of proven cardiovascular and kidney protection 4, 2. The FDA label notes this acute impairment "was observed to reverse after treatment discontinuation suggesting acute hemodynamic changes play a role" 6. This creatinine rise from 100 to 158 µmol/L falls within the expected range and should not trigger discontinuation unless accompanied by symptoms or other concerning features 1, 2, 3.